BPC-157 Capsules

BPC-157 Capsules (100 caps) — Oral Pentadecapeptide Tissue-Repair Research Compound

BPC-157 Capsules (100 x 500mcg) is supplied in Australia by Omega Peptides Australia from domestic stock, with same-day dispatch on orders placed before 12pm and an independent certificate of analysis for every batch. Commonly written as BPC 157 capsules, BPC 157 tablets, oral BPC-157 or BPC157 capsules, it is the oral capsule format of the gastric-stable pentadecapeptide studied for gastrointestinal research.

BPC-157 capsules contain the same synthetic pentadecapeptide as our lyophilised vial, presented as a pre-measured oral format with 500mcg of BPC-157 per capsule and 100 capsules per sealed bottle. BPC-157 is a fifteen-amino-acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) corresponding to a partial sequence of a protective protein found in human gastric juice. It is often written as BPC 157, BPC157 or bcp 157, and the capsule format is variously described as oral BPC-157, BPC-157 oral or, incorrectly, BPC 157 tablets.

The oral format exists because BPC-157 is unusually stable in gastric juice, remaining intact for more than 24 hours, which is why oral administration appears so frequently in the preclinical literature. Capsules are studied mainly in gastrointestinal models (ulcer, colitis, fistula and NSAID-injury designs) and in oral-route comparisons against injected peptide. At the pathway level BPC-157 acts through nitric-oxide and growth-factor signalling, activating VEGFR2 in endothelial cells and the FAK-paxillin pathway in fibroblasts.

Omega Peptides Australia supplies BPC-157 capsules made from high-purity (≥99% HPLC) COA-verified peptide, with the batch Certificate of Analysis published in our COA library. Orders placed before 12pm are dispatched the same day from within Australia.

Key research areas

• Gastrointestinal protection BPC-157 was originally characterised as a gastroprotective peptide, and oral administration is the natural route for studying it in gastric and duodenal ulcer, NSAID-lesion and colitis models. Proposed mechanisms include nitric-oxide modulation, angiogenesis in the mucosa and faster epithelial repair.
• Fistula and anastomosis healing Rodent models of gastrocutaneous, colocutaneous and oesophagocutaneous fistulas have been used to study orally delivered BPC-157, with researchers measuring closure rates, collagen deposition and vessel formation at the defect.
• Gut-brain and gut-organ axis Preclinical work investigates BPC-157 as a cytoprotective agent whose gastrointestinal effects extend to the liver, heart and brain, and oral designs are used to probe this proposed axis, including interactions with the dopamine and serotonin systems.
• Oral versus parenteral comparison Because the same peptide is available as an injectable vial and an oral capsule, research designs compare routes of administration in tendon, muscle and gastrointestinal models.
• Inflammatory bowel disease An early-phase clinical programme examined BPC-157 in inflammatory bowel disease, and rodent colitis models remain a major focus, with inflammatory markers and mucosal healing as the main endpoints.

How BPC-157 Capsules works

BPC-157 does not act through a single receptor. In vitro and rodent studies show that it activates VEGFR2 and downstream Akt-eNOS signalling in endothelial cells, increasing nitric-oxide production and angiogenesis, and that it stimulates the FAK-paxillin pathway in fibroblasts, increasing cell migration and collagen output. It also upregulates early growth response genes (egr-1 and NAB2) that regulate cytokine and growth-factor production during repair. These effects are thought to underlie the faster mucosal and connective-tissue healing reported in preclinical models.

The capsule format differs from the BPC-157 lyophilised vial in handling rather than chemistry. The vial is reconstituted into a solution of known concentration, which suits cell-culture work and injection-based animal models; the capsules deliver a fixed 500mcg of peptide each with no reconstitution or bacteriostatic water, which suits oral-administration designs and gastrointestinal models. Most linear peptides are degraded rapidly by gastric enzymes, so the oral route is only meaningful for BPC-157 because of its documented gastric stability. Human pharmacokinetic data remain limited.

Specifications

Available sizes and pricing

BPC-157 capsules are supplied in one bottle size of 100 capsules, each containing 500mcg of BPC-157, for 50mg of peptide per bottle. Laboratories that need a solution for in-vitro work or injection-based models should use the 10mg lyophilised vial instead.

• 100 caps bottle (500mcg per capsule, 50mg total) — $249.99 (about $2.50 per capsule, or $5.00 per mg)

Quality and COA verification

The BPC-157 used in every batch of capsules is independently tested by Janoshik Analytical, with HPLC confirming purity and mass spectrometry confirming the identity of the peptide against its expected molecular weight. A Certificate of Analysis is issued for every batch and published in our COA library, where the batch number on your bottle can be checked against the report. Capsules are filled to a standardised 500mcg and supplied in a sealed research-grade bottle, then packed in protective packaging for domestic transit.

Frequently bought together

• BPC-157 (10mg) — $99.99, the lyophilised vial for reconstitution-based and in-vitro designs
• TB-500 (10mg) — $99.99, the actin-binding peptide most often studied alongside BPC-157
• BPC-157 + TB-500 Blend (10mg) — $119.99, 5mg of each peptide in a single vial

Research guides

• BPC-157 research guide
• Best place to buy BPC-157 in Australia
• How to store lyophilised peptides
• COA testing explained
• Peptide reconstitution calculator
• Certificates of Analysis library

Frequently asked questions

What is BPC-157 Capsules?
BPC-157 capsules are a pre-measured oral research format of the pentadecapeptide BPC-157, with 500mcg of peptide in each capsule and 100 capsules per bottle. The peptide is a fifteen-amino-acid sequence derived from a protective protein in human gastric juice, and the oral format is used in gastrointestinal and oral-route research designs because of the peptide's unusual stability in gastric juice.

What is BPC-157 Capsules also known as?
The format is described as oral BPC-157, BPC-157 oral or BPC 157 capsules, and sometimes mislabelled as BPC 157 tablets. The peptide itself is written as BPC 157, BPC157 or bpc-157 peptide, misspelled as bcp 157, bp 157 or pbc 157, and formally called Body Protection Compound-157 or pentadecapeptide BPC 157.

How does BPC-157 Capsules work?
The peptide in the capsules is chemically identical to the lyophilised vial. In vitro and rodent studies suggest it activates VEGFR2 and nitric-oxide signalling in endothelial cells, promoting angiogenesis, and stimulates the FAK-paxillin pathway in fibroblasts, increasing cell migration and collagen production. It also modulates early growth response genes involved in cytokine regulation. The capsule simply delivers a fixed 500mcg of this peptide by the oral route.

What does the research show about BPC-157 Capsules?
Oral administration of BPC-157 in rodent models has been reported to protect the gastric and intestinal lining against ulceration and NSAID injury, to support fistula and anastomosis healing and, in some tendon and muscle models, to produce effects comparable to injected peptide. An early-phase clinical programme examined the compound in inflammatory bowel disease. Human data remain limited and BPC-157 is still an investigational research compound.

Can I buy BPC-157 Capsules at Chemist Warehouse or a pharmacy in Australia?
No. There is no BPC-157 product registered on the Australian Register of Therapeutic Goods, so Chemist Warehouse, Priceline and other retail pharmacies do not stock BPC-157 in any form. The research capsules supplied here are a laboratory reagent, not a pharmacy medicine or supplement.

Can Australian compounding pharmacies supply BPC-157 Capsules?
Compounding pharmacies in Australia prepare medicines only for an individual patient on a practitioner's prescription and do not sell peptides to the public. Omega Peptides Australia is not a pharmacy; we supply research-grade capsules with a batch COA, strictly for in-vitro laboratory use.

Do BPC-157 Capsules need to be reconstituted?
No. Each capsule already contains a fixed 500mcg of BPC-157, so no bacteriostatic water, syringes or concentration calculations are needed. If a study requires a solution, use the lyophilised 10mg vial: add bacteriostatic water slowly down the inside wall, swirl gently rather than shaking, refrigerate at 2–8°C and use within 28 days.

How should BPC-157 Capsules be stored?
Keep the bottle sealed in a cool, dry place away from direct sunlight and moisture, and close it promptly after opening. Refrigeration at 2–8°C is preferred for long-term storage. Moisture and heat are the main threats to peptide stability, so avoid humid or hot environments.

Where can I buy BPC-157 Capsules in Australia?
Directly from Omega Peptides Australia. Stock is held domestically, orders placed before 12pm are dispatched the same day, and every batch is COA-verified by Janoshik Analytical with the certificate published in our COA library. Order on this page or browse our full range of research peptides in Australia.

What does BPC-157 Capsules cost in Australia?
A bottle of 100 capsules (500mcg each, 50mg of BPC-157 in total) is $249.99, which works out to about $2.50 per capsule or $5.00 per mg of peptide. For comparison, the 10mg lyophilised vial is $99.99 (about $10.00 per mg) and the BPC-157 + TB-500 blend is $119.99.

How do I get BPC-157 Capsules online in Australia?
Add the bottle to your cart on this page and complete checkout. Orders ship from within Australia with tracked domestic delivery and discreet, unbranded packaging. Orders placed before 12pm on a business day are dispatched the same day, and later orders leave the next business day.

Is BPC-157 Capsules legal in Australia?
Omega Peptides Australia supplies BPC-157 capsules strictly for lawful in-vitro laboratory research. They are not approved by the TGA for human or veterinary use and are not sold as a medicine or supplement. Purchasers are responsible for ensuring their intended use complies with all applicable laws.

What is the difference between BPC-157 capsules and the injectable vial in research use?
The chemistry is identical; the difference is handling and route. The 10mg lyophilised vial is reconstituted into a solution of known concentration for cell-culture assays and the injection-based animal models that dominate the tendon and muscle literature. The capsules deliver a fixed 500mcg per unit by the oral route, which suits gastrointestinal models and oral-versus-parenteral comparisons. Both formats are COA-verified.

⚠ For in-vitro research and laboratory use only. Not for human or veterinary use.